Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

• DOI: 10.1016/j.iotech.2024.100728
• Publication Date: 2024-08-23T10:40:05Z
• Authors: D. König; B. Kasenda; M. Sandholzer; A. Chirindel; A. Zingg; R. Ritschard; H. Thut; K. Glatz; E.A. Kappos; D. Schaefer; C. Kettelhack; J. Passweg; K. Baur; A. Holbro; A. Buser; D. Lardinois; L.T. Jeker; N. Khanna; F. Stenner; M.S. Matter; N. Rodrigues Mant...; M. Binder; A. Zippelius; H. Läubli
• Keywords: Tumor-infiltrating lymphocytes; Adoptive Cell Transfer; Cell therapy; Adoptive immunotherapy

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a personalized immunotherapy. The efficacy of TIL-ACT has been demonstrated prospectively in patients advanced melanoma but not limited to patients. Many are refractory TIL-ACT, however, or their cancer becomes resistant. Combining anti-programmed death protein 1 (anti-PD-1) antagonize the immunosuppressive tumor microenvironment may synergize enhance antitumor potential. We set up Between 2020 and 2022, we enrolled 11 9 underwent TIL transfer (median transfused number: 66.25 × 10 nivolumab feasible safe. Larger trials needed further determine this combination.